Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of angiotensin modulators according to APOE-ϵ4 alleles and the ACE insertion/deletion polymorphism in Alzheimer's disease.

Acta neuropsychiatrica - 1 Dec 2023

Oliveira Fabricio Ferreira de, Almeida Sandro Soares de, Chen Elizabeth Suchi, Smith Marilia Cardoso, Bertolucci Paulo Henrique Ferreira

Abstract excerpt

OBJECTIVE: In Alzheimer's disease (AD), angiotensin II receptor blockers (ARBs) could reduce cerebrovascular dysfunction, while angiotensin-converting enzyme inhibitors (ACEis) might increase brain amyloid-β by suppressing effects of the angiotensin-converting enzyme 1, an amyloid-β-degrading enzyme. However, ACEis could benefit patients with AD by reducing the amyloidogenic processing of the amyloid precursor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alzheimer's disease research and treatments

Share to Angiotensin-Converting Enzyme Inhibitors

Share to Angiotensin Receptor Antagonists

Share to Angiotensins

Share to Apolipoproteins E

Share to Pharmacogenetics

Source

Identifiers

PMID: 37605989
DOI: 10.1017/neu.2023.38

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of angiotensin modulators according to APOE-ϵ4 alleles and the ACE insertion/deletion polymorphism in Alzheimer's disease.PMID 37605989Read ↗

Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.Semantic proximity Read ↗

Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer's disease depend upon stratification according to APOE-ϵ4 carrier status.Semantic proximity Read ↗

Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia.Semantic proximity Read ↗

Large Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of Alzheimer's DiseaseSemantic proximity Read ↗

The Impact of Angiotensin-Converting Enzyme Gene on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease.Semantic proximity Read ↗

Angiotensin-converting enzyme polymorphisms AND Alzheimer's disease susceptibility: An updated meta-analysis.Semantic proximity Read ↗

Pharmacogenetic Considerations in the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease.Semantic proximity Read ↗

Angiotensin converting enzyme deletion allele in different kinds of dementia disorders.Semantic proximity Read ↗

Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.Semantic proximity Read ↗

Genetic influences on Alzheimer's disease: evidence of interactions between the genes APOE, APOC1 and ACE in a sample population from the South of Brazil.Semantic proximity Read ↗

ACE inhibition increases Alzheimer’s disease risk by promoting tau phosphorylationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.